FindTrial
Sign In

TSR-022

DRUG2 trials

Sponsors

Tesaro, Inc.

Conditions

Advanced CancerMetastatic CancerNeoplasmsNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer Stage IIIBSolid Tumor

Phase 1

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Active, not recruitingNCT02817633
Tesaro, Inc.Neoplasms
Start: 2016-07-08End: 2027-03-01Updated: 2025-10-28
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
CompletedNCT03307785
Tesaro, Inc.Advanced Cancer, Metastatic Cancer, Neoplasms +4
Start: 2017-10-12End: 2024-12-11Updated: 2025-11-25

Related Papers

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
Clinical Cancer Research2025-06-247 citations
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
Clinical Cancer Research2025-06-243 citations
AMBER part 2F: Cobolimab in combination with dostarlimab in treatment-naïve patients with locally advanced/metastatic and/or unresectable hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2025-01-271 citations
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
BMJ Open2024-08-0110 citations
596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy
Regular and Young Investigator Award Abstracts2023-10-314 citations
Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.
2023-10-184 citations
Dostarlimab: A Review.
2022-07-2639 citations
Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).
Journal of Clinical Oncology2022-06-0172 citations
AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma.
Journal of Clinical Oncology2022-06-0110 citations
Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours
British Journal of Clinical Pharmacology2022-03-3125 citations
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
Journal for ImmunoTherapy of Cancer2022-03-0116 citations
Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy
Cancer Science & Research2021-12-30
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
European Journal of Cancer2021-09-2724 citations
IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer.
Journal of Clinical Oncology2019-05-2010 citations